Algernon Pharmaceuticals is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).
The Algernon drug development program was the brainchild of Dr. Mark Williams, the Company’s CSO, whose innovative approach to drug discovery was developed over many years as senior scientist in the drug development industry. The company and its business model is highly capital efficient and strives to deliver maximum shareholder value.
Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.
Phase II Clinical Trials Being Planned by Algernon
of Phase II trials Succeed*